Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133417) titled 'Study of the Efficacy and Safety of Maribavir for Cytomegalovirus (CMV) Infection Following Hematopoietic Stem Cell Transplantation in Children and Adolescents' on Sept. 26.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Children's Hospital of Fudan University
Condition:
Cytomegalovirus Infection Following Hematopoietic Stem Cell Transplantation
Intervention:
Experimental group:Maribavir: body weight >=25 kg, 400 mg (2 x 200 mg) orally twice daily
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-08
Target Sample Size: Experimental group:20; ...